New guidance to prevent the tragedy of unrecognized esophageal intubation

(August 17, 2022) — Oesophageal intubation describes the unintended insertion of a breathing tube into the oesophagus (the tube leading to the stomach) instead of the windpipe (trachea).  If this is not promptly recognised it causes brain damage or death. There have been a few high-profile cases of unrecognised oesophageal intubation recently, and often such cases result in the deaths of otherwise well patients having routine procedures (see links below).

 

New guidance published by Anaesthesia (a journal of the Association of Anaesthetists) provides the first ever consensus guidance on this subject, designed to reduce avoidable deaths and injury. The authors are an international team that include Dr Nicholas Chrimes, Consultant, Department of Anaesthesia, Monash Medical Centre, Melbourne, Australia and Professor Tim Cook, Consultant in Anaesthesia and Intensive Care Medicine, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK, and Honorary Professor, School of Medicine, University of Bristol, UK.

Mistakenly inserting the breathing tube into the oesophagus instead of the trachea can occur for a variety of reasons including distorted anatomy, technical difficulties, clinician inexperience or movement of the tube.

Oesophageal intubation is relatively common. Every airway management clinician would have mistakenly intubated the oesophagus on multiple occasions during their career. Usually this is rapidly identified and does not result in harm. Not recognising that oesophageal intubation has occurred is extremely rare but nearly always fatal. One UK survey1 found that it caused six deaths in a single year. However, as publicly reporting these events is not mandatory, determining the exact incidence is difficult.

Usually, oesophageal intubation is easily detected and corrected without causing any harm. In most settings (and routinely as a standard of practice during anaesthesia in most high-income countries), monitors are connected to the breathing tube that detect carbon dioxide, which is only produced by the lungs and isn’t present in the stomach. Detecting carbon dioxide therefore usually confirms correct placement of the breathing tube in the trachea. If carbon dioxide is not detected this usually indicates the breathing tube is in the oesophagus.

In cases of unrecognised oesophageal intubation, the inability to detect carbon dioxide following placement of a breathing tube is often mistakenly attributed to the occurrence of cardiac arrest. However, while a cardiac arrest is a frequent consequence of the lack of oxygen resulting from oesophageal intubation, when the breathing tube is correctly placed in the trachea, cardiac arrest due to other causes should still result in some carbon dioxide being able to be detected. The guidelines therefore re-emphasise earlier advice that cardiac arrests should not result in the complete absence of carbon dioxide unless the breathing tube is incorrectly placed.

The new guidance also emphasises removing the breathing tube immediately as a precaution if carbon dioxide cannot be detected, unless this would be dangerous, which is rarely the case. In the unusual situation where removing the tube by default is thought to place the patient at risk, clear recommendations are provided on alternative ways to exclude oesophageal intubation and correct other causes of absent carbon dioxide.

It also recommends that exhaled carbon dioxide monitoring and pulse oximetry (which measures oxygen levels in the blood) should be available and used for all procedures that require a breathing tube, and that a videolaryngoscope (an intubation device fitted with a video camera to improve the view) is used to insert the breathing tube whenever possible to ensure correct placement. Another factor that has contributed to some of these tragic deaths is mistaking other similar looking readings on monitors for carbon dioxide – so the guidance recommends standardising and improving the distinctiveness of how these readings are displayed on the screen.

 

Beyond these technical factors, the new guidance notes the contribution to these tragic outcomes made by the stress and confusion that arises, even among experienced medical teams, when such emergencies occur cannot be underestimated. The impact of such factors on the management of crises has long been recognised in other safety conscious industries such as aviation but is a relevantly recent addition to the understanding of adverse outcomes in medicine. Techniques are advocated by the guidance to help address this.

The authors conclude: “The continued occurrence of death and serious harm from unrecognised oesophageal intubation worldwide suggests that an approach to prevention solely focused on stressing removal of the tube if no carbon dioxide is detected is not a complete solution. This guideline emphasises this point but also provides a more comprehensive approach that addresses both technical and human factors-based contributions to the occurrence of unrecognised oesophageal intubation. The emphasis is on the trigger for tube removal being identification of an unacceptable risk rather than a definitive diagnosis that it is misplaced.”

Dr Mike Nathanson, President of the Association of Anaesthetists, said: “As the authors note, cases of unrecognised oesophageal intubation still occur and may, sadly, lead to death or brain injury. We welcome this important international initiative; we hope the guidance will be widely disseminated. Prevention of future incidents requires education, technological innovation, and a better understanding of the human factors involved. The suggestion of two-person confirmation of the presence of exhaled carbon dioxide is welcome, and we hope this can be introduced into clinical practice.”

 

 

Dr Nicholas Chrimes, Consultant, Department of Anaesthesia, Monash Medical Centre, Melbourne, Australia. T) +61 401 137119 E) nicholaschrimes@gmail.com

Professor Tim Cook (Consultant in Anaesthesia and Intensive Care Medicine, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK, and Honorary Professor, School of Medicine, University of Bristol, UK. T) +44 7970 025209 E) timcook007@gmail.com

Dr Mike Nathanson, President of the Association of Anaesthetists. Please contact via text or e-mail first to arrange interview. T) +44 7973 478 683 E) president@anaesthetists.org

Alternative contact: Tony Kirby of Tony Kirby PR. T) +44 7834 385827 E) tony@tonykirby.com

 

For some more detailed background on unrecognised oesophageal intubation, click here

 

1 For more information on the UK survey, see:  https://www.nationalauditprojects.org.uk/NAP4_home

 

Several case studies are available to accompany this new guidance.

Case study 1, Australia – details including Coroner’s report published and available, click here

Case study 2, Australia, certain details published, Coroner’s report not published, click here

Case study 3, UK – Glenda Logsdail – details including Coroner’s report and news reports from inquest published, click here

 

For other examples of cases of unrecognised oesophageal intubation in Australia and the UK, see:

https://www.universalairway.org/puoi/cases/australia

https://www.universalairway.org/puoi/cases/uk

 

 


Association of Anaesthetists of Great Britain and Ireland (AAGBI), 17.08.2022 (tB).

Schlagwörter: , ,

MEDICAL NEWS

IU School of Medicine researchers develop blood test for anxiety
COVID-19 pandemic increased rates and severity of depression, whether people…
COVID-19: Bacterial co-infection is a major risk factor for death,…
Regenstrief-led study shows enhanced spiritual care improves well-being of ICU…
Hidden bacteria presents a substantial risk of antimicrobial resistance in…

SCHMERZ PAINCARE

Hydromorphon Aristo® long ist das führende Präferenzpräparat bei Tumorschmerz
Sorgen und Versorgen – Schmerzmedizin konkret: „Sorge als identitätsstiftendes Element…
Problem Schmerzmittelkonsum
Post-Covid und Muskelschmerz
Kopfschmerz bei Übergebrauch von Schmerz- oder Migränemitteln

DIABETES

Wie das Dexom G7 abstrakte Zahlen mit Farben greifbar macht…
Diabetes mellitus: eine der großen Volkskrankheiten im Blickpunkt der Schmerzmedizin
Suliqua®: Einfacher hin zu einer guten glykämischen Kontrolle
Menschen mit Diabetes während der Corona-Pandemie unterversorgt? Studie zeigt auffällige…
Suliqua® zur Therapieoptimierung bei unzureichender BOT

ERNÄHRUNG

Positiver Effekt der grünen Mittelmeerdiät auf die Aorta
Natriumaufnahme und Herz-Kreislaufrisiko
Tierwohl-Fleisch aus Deutschland nur mäßig attraktiv in anderen Ländern
Diät: Gehirn verstärkt Signal an Hungersynapsen
Süßigkeiten verändern unser Gehirn

ONKOLOGIE

Strahlentherapie ist oft ebenso effizient wie die OP: Neues vom…
Zanubrutinib bei chronischer lymphatischer Leukämie: Zusatznutzen für bestimmte Betroffene
Eileiter-Entfernung als Vorbeugung gegen Eierstockkrebs akzeptiert
Antibiotika als Störfaktor bei CAR-T-Zell-Therapie
Bauchspeicheldrüsenkrebs: Spezielle Diät kann Erfolg der Chemotherapie beeinflussen

MULTIPLE SKLEROSE

Multiple Sklerose: Aktuelle Immunmodulatoren im Vergleich
Neuer Biomarker für Verlauf von Multipler Sklerose
Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?

PARKINSON

Meilenstein in der Parkinson-Forschung: Neuer Alpha-Synuclein-Test entdeckt die Nervenerkrankung vor…
Neue Erkenntnisse für die Parkinson-Therapie
Cochrane Review: Bewegung hilft, die Schwere von Bewegungssymptomen bei Parkinson…
Technische Innovationen für eine maßgeschneiderte Parkinson-Diagnostik und Therapie
Biomarker und Gene: neue Chancen und Herausforderungen für die Parkinson-Diagnose…